Use of Injectable Valproic Acid in Status Epilepticus

1993 ◽  
Vol 5 (3) ◽  
pp. 154-159 ◽  
Author(s):  
M. Giroud ◽  
D. Gras ◽  
A. Escousse ◽  
R. Dumas ◽  
G. Venaud
Keyword(s):  
Valproic Acid ◽  
Status Epilepticus

scholarly journals Valproic Acid Administration in Management of Status Epilepticus Causing Reye’s Syndrome

2021 ◽  
Vol 07 (01) ◽  
pp. 044-046
Author(s):  
Pooja Prabhakar Kamath
Keyword(s):  
Valproic Acid ◽  
Status Epilepticus ◽  
Hepatic Dysfunction ◽  
Rare Condition ◽  
Normal Serum ◽  
Reye's Syndrome ◽  
Serum Glutamic Oxaloacetic Transaminase ◽  
Viral Illness ◽  
Laboratory Investigations ◽  
Serum Ammonia

Abstract Introduction Valproic acid is commonly used to treat seizures in children. Regular use of valproic acid is known to cause hepatic dysfunction, and in extremely rare cases, it is known to have caused Reye’s syndrome. There are very few reports of Reye’s syndrome caused by valproic acid use. Methods A 2-year asymptomatic girl underwent modified Blalock–Taussig shunt surgery for correction of tetralogy of Fallot. Postoperatively the girl developed status epilepticus, which did not subside with initial use of intravenous midazolam and phenytoin sodium. She eventually responded to two doses of intravenous valproic acid administered 10 minutes apart. She developed depressed sensorium and was put on mechanical ventilation. The following day’s laboratory investigations revealed raised levels of serum ammonia, serum glutamic-oxaloacetic transaminase (SGOT), and serum glutamic-pyruvic transaminase (SGPT) with normal serum bilirubin. Thus, a diagnosis of Reye’s syndrome was established. The patient succumbed to disease 2 days later. Discussion Reye’s syndrome is a rare and a fulminant illness seen typically in children following a viral illness and/or use of salicylates or other medications. There are rare reports of Reye’s syndrome following use of medications like valproic acid. This patient had a noninflammatory encephalopathy with hepatic dysfunction following two doses of valproic acid. Conclusion There are very few reports on Reye’s syndrome in the literature as it is a rare condition and diagnosis is difficult. Knowledge of the presentation of Reye’s syndrome is essential for treatment and management. When using drugs like valproic acid in children, liver enzymes and serum ammonia levels should be monitored.

Status Epilepticus Associated with the Combination of Valproic Acid and Clomipramine

1997 ◽  
Vol 19 (1) ◽  
pp. 71-73 ◽  
Author(s):  
J. C. DeToledo ◽  
H. Haddad ◽  
R. E. Ramsay
Keyword(s):  
Valproic Acid ◽  
Status Epilepticus

Valproic acid treatment of experimental status epilepticus

1992 ◽  
Vol 12 (3) ◽  
pp. 199-205 ◽  
Author(s):  
Nancy Y. Walton ◽  
David M. Treiman
Keyword(s):  
Valproic Acid ◽  
Status Epilepticus ◽  
Acid Treatment ◽  
Experimental Status

scholarly journals Valproic acid as adjuvant treatment in generalized convulsive status epilepticus for adults admitted to the ICU on (VALSE): randomized double blind clinical trial (Preprint)

2020 ◽  
Author(s):  
Tarek Sharshar ◽  
Omar Ben Hadj Salem ◽  
Raphael Porcher ◽  
Lamiae Grimaldi ◽  
Nicholas Heming ◽  
...  
Keyword(s):  
Valproic Acid ◽  
Status Epilepticus ◽  
Controlled Trial ◽  
Standard Of Care ◽  
Medical Emergency ◽  
Convulsive Status Epilepticus ◽  
Second Line ◽  
Double Blind ◽  
Good Tolerability ◽  
Intent To Treat

BACKGROUND Generalized convulsive status epilepticus (GCSE) is a frequent medical emergency. Treatment focuses on administration of benzodiazepines followed by a second line antiepileptic drug (AED). Despite this stepwise strategy, GCSE is not controlled in a quarter of patients and is associated with protracted hospitalization, high-mortality and long-term disability. OBJECTIVE We aimed to show that the administration of valproic acid (VPA) may be suited as a complement of the first and second-line treatment, because of antiepileptic efficacy, neuroprotective properties and good tolerability. METHODS We conducted a multicenter, double-blind, randomized controlled trial comparing VPA to placebo in adults admitted to intensive care units (ICU) for GCSE in France. All patients received standard of care including a benzodiazepine and a second-line AED (except VPA) at the discretion of the treating medical team. In the intervention arm, VPA was administered intravenously as a loading dose of 30mg/kg over 15 minutes followed by a continuous infusion of 1 mg/kg/h over the next 12 hours. In the placebo group, an identical IV administration of 0.9 % saline was used. The primary outcome was the proportion of patients discharged alive from hospital by day 15. Secondary outcomes were frequency of refractory and super-refractory GCSE; ICU-related morbidity; adverse events related to VPA, and cognitive dysfunction at 3 months. Statistical analyses will be performed according to the intent-to-treat principle. Ethics Committee of Saint-Germain-en-Laye, France, initial approval received on May 14 2012. Results will be disseminated via peer-reviewed publication and presentation at international conferences. RESULTS The first patient was randomized on February 18, 2013 and the last patient on July 7, 2018. 245 (99%) out of 248 planned patients were enrolled across 20 ICUs. At present, data management is still ongoing, and all parties involved in the trial remain blinded.Research CONCLUSIONS This is the first multicentre randomized double-blind controlled trial that assesses whether Valproic Acid can be useful as an adjuvant therapy to recommended first and second line anti-epileptic drugs for improving the outcome of GCSE. CLINICALTRIAL NCT01791868 (registered on May 2012).

scholarly journals Experience in using injectable valproic acid (convulex) in patients with serial epileptic seizures and status epilepticus at the prehospital stage

2012 ◽  
Vol 0 (1S) ◽  
pp. 53
Author(s):  
Anna Valeryanovna Lebedeva ◽  
V A Karlov ◽  
A M Sidorov ◽  
V L Baratashvili ◽  
V E Khomutov
Keyword(s):  
Valproic Acid ◽  
Status Epilepticus ◽  
Epileptic Seizures

Valproic Acid as Adjuvant Treatment for Convulsive Status Epilepticus

2022 ◽  
Author(s):  
Tarek Sharshar ◽  
Raphael Porcher ◽  
Pierre Asfar ◽  
Lamiae Grimaldi ◽  
Jabot Julien ◽  
...  
Keyword(s):  
Valproic Acid ◽  
Status Epilepticus ◽  
Adjuvant Treatment ◽  
Convulsive Status Epilepticus
Sign in / Sign up

Export Citation Format

Share Document